Cancer genomic medicine in Japan and the roles of pharmacists

Tohru Aomori, Hiroomi Sakurai, Hiroshi Nishihara

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer genomic medicine (CGM) is a medical service that provides optimized treatment for each patient based on genes, biomarkers, environment, and lifestyle. In Japan, the approval of designed core hospitals for CGM started in 2017. In June 2019, two types of cancer gene panel tests became available in the national health insurance system, and CGM was socially implemented. While CGM is still in its infancy and there are some issues that need to be resolved, there are cases where the treatment has shown dramatic results. The present review highlights the CGM system in Japan, the issues it faces, and the role of pharmacists in this system.

Original languageEnglish
Pages (from-to)242-245
Number of pages4
JournalPharmacogenetics and Genomics
Volume32
Issue number6
DOIs
Publication statusPublished - 2022 Aug 1

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Cancer genomic medicine in Japan and the roles of pharmacists'. Together they form a unique fingerprint.

Cite this